Axsome Therapeutics, Inc.

This study tested whether the drug AXS-12 could safely control two main narcolepsy symptoms—cataplexy (sudden muscle weakness) and excessive daytime sleepiness—over a longer period. It involved 68 people with narcolepsy who had already taken part in a previous trial. For 24 weeks…

This large study tested whether a daily medication called solriamfetol could help control symptoms in adults with ADHD. Over 500 adults took either the medication or a placebo pill for six weeks. Researchers measured changes in ADHD symptoms to see if the treatment was effective …

This study tested whether a medication called solriamfetol helps adults with major depressive disorder. 346 participants were randomly assigned to receive either the medication or a placebo pill for 6 weeks. Researchers measured changes in depression symptoms and monitored for si…

This study tested a two-drug combination called AXS-07 for treating migraine attacks. It was for adults who had tried a common type of migraine pill (a CGRP inhibitor) and didn't get enough relief. Participants took the study drug at home for up to 8 weeks to treat up to four of …

This study tested whether a single dose of a new oral medication called AXS-07 could stop migraine pain and the most bothersome symptom within two hours. It involved 302 adults with migraines who were randomly assigned to receive either the medication or a placebo pill when a mig…

This study tested whether a medication called solriamfetol could improve mental sharpness in adults with obstructive sleep apnea. The 59 participants had both excessive daytime sleepiness and problems with cognitive function. Over 5 weeks, researchers compared the effects of the …

This study tested whether the medication AXS-05 could safely reduce agitation in people with Alzheimer's disease. 408 participants with Alzheimer's-related agitation were randomly assigned to receive either the drug or a placebo for 5 weeks. Researchers measured changes in agitat…

This study tested whether AXS-05 is safe and effective for reducing agitation in people with Alzheimer's disease over a long period. 456 participants who had already shown benefit from AXS-05 in previous studies were either kept on the medication or switched to placebo to see if …